Our Thinking

Alzheimer's drug study yields positive results, say makers Eisai and Biogen

π—§π—΅π—Άπ—»π—Έπ™π˜Όπ™Žπ™. The Biogen/Eisai investigational Alzheimer's monoclonal antibody lecanemab achieved its main endpoint in a large clinical trial. With the FDA planning to review it in early January 2023, what will this drug mean for the treatment of Alzheimer’s disease?

Read more about this here: https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-says-alzheimers-drug-succeeds-slowing-cognitive-decline-2022-09-27/


Contact us to learn how we can help your team to make better marketing decisions based on better market research.